Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Paragraph IV isnt broken. Its being outmaneuveredpredictably.
If youve spent the last few years building (or defending) a Paragraph IV strategy, youve probably seen the same pattern play out: the certainties you rely ongeneric timing, litigation levera…
Predictable by Design: How Brands Outmaneuver Your Paragraph IV Strategy Read Post »
The 180-Day Exclusivity Trap: Why First Filer Wins on PaperBut Loses in the Real World
In generic and biosimilar drug development, the first filer rule is supposed to feel like a cheat code.
File early, trigger 180 days of exclusivity, capture market s…
The First-Filer’s Trap: Why 180-Day Exclusivity Fails Without a Supply Chain Moat Read Post »
Most companies chase the same thing: blockbuster drugs with massive revenue potential. But the smart play in 2026and beyondmay be almost the opposite: stop chasing unloved orphan patents with blockbuster assumptions and start monetizing them with a dis…
Stop Chasing Blockbusters: The High-Margin World of Unloved Orphan Drug Patents Read Post »
Your regulatory team should not treat patents like an afterthought.
Agonizingly common scenario: a strategy meeting focused on label language, PMRs, launch timelinesand then, somewhere down the line, a patent notice lands on the legal desk like a meteo…
Why Your Regulatory Team Needs to Think Like Drug Patent Litigators Read Post »
Big pharma doesnt lose its edge because R&D gets slower.
It loses its edge because R&D gets blindsided.
That late pivot momentwhen a promising program suddenly hits patent/market access constraints, generic entry timelines, or unexpected exclus…
Ever notice how people talk about biosimilars like the hard part is proving theyre the same?
That partbioequivalenceis undeniably important. But if youre building a biologics strategy, you quickly learn the truth: bioequivalence is often the easy part….
Why Bioequivalence Is the Easy Part and Freedom to Operate Is the Cliff Read Post »
Pharma doesnt win by having the most patents. It wins by having the right ones at the right cost.
Theres a seductive idea making the rounds in IP circles: Just file enough to keep the portfolio safe. Minimal filings. Low immediate spend. A lighter lift…
The Safe Patent Portfolio Trap: Why Minimal Filing Costs Pharma a Decade of Growth Read Post »
A $50 million notice letter isnt just expensiveits a warning about how a single Paragraph IV mistake can compound into real money, real delay, and real reputational damage.
If youve ever sat through a life sciences deal where counsel, business teams, a…
Get new actionable insights and updates from BiotechBlog
